Quick Search 
Drug News & Perspectives
Register or sign in

Drug News Perspect 2003, 16(7): 413
ISSN 0214-0934
Copyright 2003 Clarivate
CCC: 0214-0934

New incretin-based antidiabetic medications may be introduced into clinical practice within 3 to 5 years.

Incretins and Their Analogues as New Antidiabetic Drugs

by Michael A. Nauck, Juris J. Meier and Werner Creutzfeldt


Glucagon-like peptide 1 (GLP-1) is a gut (incretin) hormone with multiple actions that could potentially contribute to an antidiabetic effect. This includes: (a) glucose-dependent insulinotropic actions; (b) glucagonostatic actions; (c) a reduction in appetite/promotion of satiety leading to reduced food intake and weight reduction; (d) the deceleration of gastric emptying; and (e) the stimulation of islet growth, differentiation and regeneration. Thus, multiple aspects of the type 2 diabetic phenotype can potentially be improved or even corrected by GLP-1. The native gut hormone, however, after intravenous injection or absorption from subcutaneous depots, is proteolytically degraded and eliminated from the circulation too quickly to be useful for the treatment of diabetes. GLP-1 derivatives (receptor agonists) with prolonged pharmacokinetics that promise a potential for clinical use in the near future are being developed. © 2003 Prous Science. All rights reserved.

Full Text: HTMLPDF 

© Clarivate. All rights reserved.
Copyright NoticeTerms of UsePrivacy StatementCookie PolicyManage cookie preferences